Ulcerative Colitis Clinical Trial
Official title:
Evaluation of PillCam IBD Capsule Endoscopy System in Visualization of Lesions in the Colon Indicative of Ulcerative Colitis Disease
Study Hypothesis UC Disease affects the colon. PillCam IBD may be used for visualization of
the colon mucosa in UC Disease patients. This study is designed to evaluate the yield and
clinical impact of IBD capsule in detecting lesions associated with UC Disease and to
determine the agreement between PillCam Platform with the IBD capsule and optical
colonoscopy in the evaluation of UC disease extent.
Primary Scientific Objective To evaluate the agreement between PillCam IBD system and
optical colonoscopy in the evaluation of UC disease extent (Non-active disease, Proctitis,
Left-sided colitis, Pancolitis)
Proposed Design Established UC disease patients whose clinical condition suggests ongoing
disease activity, aged 18 years and up, who have no evidence of symptomatic stricture or
other obstruction that would prevent capsule passage will be enrolled in this study.
Patients will undergo bowel prep, followed by a PillCam IBD capsule examination and
colonoscopy examination.
The Rapid videos will be evaluated by two readers, each from a different site, the
colonoscopy videos will be evaluated by two other physicians, at the sites
INCLUSION CRITERIA
All subjects must fulfill all of the following inclusion criteria:
- Patients ages 18 years and up
- Patient has known UC according to physician discretion
- Patient has at least one positive inflammatory marker from the following:
- ESR
- CRP
- CBC
- Patient is indicated and eligible for a standard of care colonoscopy examination
- Patient agrees to sign consent form
EXCLUSION CRITERIA
The presence of any of the following will exclude a patient from study enrollment:
- Crohn's Disease
- Antibiotic Associated Colitis
- Stool positive for O&P (C&S within 3 months of enrollment)
- Other known infectious cause of increased symptoms
- Known intestinal obstruction or current obstructive symptoms, such as severe abdominal
pain with accompanying nausea or vomiting.
- Definite long stricture seen on radiological exam.
- Non-steroidal anti-inflammatory drugs including Aspirin, (twice weekly or more) during
the 4 weeks preceding enrollment
- Suspected GI stricture, followed by patency capsule study or other imaging study that
could not prove patency of the GI tract.
- Patient has had prior abdominal surgery of the gastrointestinal tract in the last 6
months, other than uncomplicated procedures that would be unlikely to lead to bowel
obstruction based on the clinical judgment of the investigator.
- Patient is expected to undergo MRI examination within 7 days after ingestion of the
capsule.
- Patient with known gastrointestinal motility disorders.
- Subjects with known or suspected delayed gastric emptying
- Patient suffers from any condition, such as swallowing problems, which precludes
compliance with study and/or device instructions.
- Patient has Type 1 or Type II Diabetes.
- Patient has any allergy or other known contraindication to the medications used in the
study.
- Patient has any condition, which precludes compliance with study and/or device
instructions.
- Women who are either pregnant or nursing at the time of screening, or are of
child-bearing potential and do not practice medically acceptable methods of
contraception.
- Concurrent participation in another clinical trial using any investigational drug or
device.
- Patient suffers from a life threatening condition
- Patients with history or clinical evidence of renal disease and/or previous clinically
significant laboratory abnormalities of renal function parameters.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05702879 -
Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
|
||
Not yet recruiting |
NCT05953402 -
A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Recruiting |
NCT03950232 -
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03124121 -
Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels
|
Phase 4 | |
Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
Withdrawn |
NCT04209556 -
A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis
|
Phase 2 | |
Terminated |
NCT00061282 -
Clotrimazole Enemas for Pouchitis in Children and Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT04398550 -
SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis
|
N/A | |
Recruiting |
NCT04314375 -
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
|
Phase 4 | |
Active, not recruiting |
NCT04857112 -
Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Active, not recruiting |
NCT04033445 -
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
Active, not recruiting |
NCT06221995 -
Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
|
||
Recruiting |
NCT04767984 -
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT06071312 -
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
|
Phase 1/Phase 2 | |
Completed |
NCT03760003 -
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
|
Phase 2 | |
Not yet recruiting |
NCT05539625 -
Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis
|
Phase 2 |